anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Preoperative peritumoral edema (PTE) in intracranial meningiomas is known to be a risk factor for postoperative recurrence. However, there are two groups: those in which preoperative PTE remains and those in which preoperative PTE receded after tumor removal. We aimed to investigate whether postoperative PTE could improve the prediction of prognosis of meningioma with preoperative PTE. We retrospectively reviewed postoperative MRI scans in 3 months after operation of 371 patients with preoperative PTE of meningioma that underwent surgery between 2015 and 2017. All the patients were classified into two different groups according to whether had postoperative PTE receded within 3 months after operation. Clinical manifestations, histopathology characteristics, radiology data and follow-up outcomes were noted. student's t-test and chi-square test for independence were used to compare clinical characteristics. Univariate and multivariate Cox analysis and Kaplan‒Meier methods were utilized to determine the independent effect of postoperative PTE on postoperative recurrence. Multivariate Cox analyses showed that the risk factors of meningioma recurrence: high WHO grades (HR = 4.989, P<0.001), superior sagittal sinus invasion (HR = 2.290, P = 0.047), postoperative PTE in 3 months after operation (HR = 1.804, P = 0.044) and STR (HR = 3.940, P = 0.003). Kaplan-Meier model showed that the progression-free survival of patients with postoperative PTE are shorter than who with postoperative PTE receded in 3 months after operation (HR = 3.30, P = 0.006). According to our research, we found that postoperative PTE in 3 months after operation is related to the outcomes of meningioma with preoperative PTE. Besides, we demonstrated that there were also some factors for recurrence: male, high WHO grades, superior sagittal sinus invasion and STR. These findings highlight the need for prospective study.
Diabetic nephropathy is the major contributor to end stage renal disease worldwide. Extracorporeal shock wave treatments (ESWT) with low-intensity was reported to be beneficial in inducing cell regeneration and reducing inflammation and have been successfully used for bone fracture, cardiac ischemia, and erectile disorders. In this study, sixty patients with stage III \& IV (15\<=estimated glomerular filtration rate (eGFR)\<60 ml/min/1.73m2) will be recruited and allocated to control and experimental groups in a 1:1 ratio. In experiment group, a total of 1200 shockwaves, with low energy density 0.1mj/mm2 and a frequency of 120 shocks/min, will be applied per kidney per treatment session. The treatment will be given twice a week for 3 consecutive weeks, followed by 3 weeks of recess and an additional series of 6 sessions (totally 12 times). Patients in each group will be evaluated with eGFR, urine protein-creatinine ration, blood pressure, and biochemistry data at the beginning (index day) and 12 months after starting of the therapy. (Outcome time point: 12 months)
Sparassis latifolia (SL) has been reported to exhibit anti-obesity effects in high-fat diet animal models, yet research into its mechanisms of action remains limited. Therefore, this study aimed to elucidate the mechanisms behind the anti-obesity activity of SL's 30% ethanol extract (SL30E) using 3T3-L1 cells in an in vitro setting. SL30E effectively mitigated the accumulation of lipid droplets and triacylglycerol. SL30E downregulated PPARγ and CEBPα protein levels. The diminishment of PPARγ and C/EBPα, facilitated by SL30E, was impeded by the knockdown of β-catenin using β-catenin-specific siRNA. Furthermore, SL30E was observed to increase the protein levels of ATGL and p-HSL, while it concurrently decreased the protein levels of perilipin-1. SL30E downregulated p62/SQSTM1 protein level and upregulated LC3-II protein level. Moreover, SL30E was demonstrated to elevate the protein levels of p-AMPK and PGC-1α. The results indicate that SL30E inhibits lipid accumulation by suppressing adipogenesis and inducing lipolysis, lipophagy, and thermogenesis in 3T3-L1 cells. These observations provide potential insights into the mechanisms underlying the anti-obesity effects of SL, contributing valuable information to the existing body of knowledge.
In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) with uninterrupted chest compressions. Chest compressions with the two thumb-encircling hands technique were performed by the same Basic Life Support (BLS) instructor at a rate of 100 compressions per minute and at a depth of about 1.5 inches according to the European Resuscitation Council guidelines of 2010 year.
The baculovirus-insect cell vector system is used as a high efficiency eukaryotic cloning and expression method for the production of recombinant proteins. A major application of this system is also in the development of rDNA vaccines for a variety of important human and animal diseases. This system is used to express a variety of candidate vaccine immunogens derived from the envelope gene of Human Immunodeficiency Virus (HIV). The envelope protein of HIV is the most promising candidate in the development of vaccines and diagnostics for AIDS since it has been shown that the envelope glycoprotein represents the major target antigen of AIDS virus. Recombinant baculoviruses have been constructed which express a variety of domains of the envelope gene (env), including gp 160 and gp 120. Expression of the recombinant HIV baculoviruses in insect cells results in the production of glycoproteins which are reactive with HIV-specific serum. HIV antigens produced from some of these recombinants have been successfully employed in a variety of immunodiagnostic assays including ELISA, Western Blotting and radioimmunoprecipitation.
Plants typically activate distinct defense pathways against various pathogens. Heightened resistance to one pathogen often coincides with increased susceptibility to another pathogen. However, the underlying molecular basis of this antagonistic response remains unclear. Here, we demonstrate that mutants defective in the transcription factor ETHYLENE-INSENSITIVE 3-LIKE 2 (OsEIL2) exhibited enhanced resistance to the biotrophic bacterial pathogen Xanthomonas oryzae pv oryzae and to the hemibiotrophic fungal pathogen Magnaporthe oryzae, but enhanced susceptibility to the necrotrophic fungal pathogen Rhizoctonia solani. Furthermore, necrotroph-induced OsEIL2 binds to the promoter of OsWRKY67 with high affinity, leading to the upregulation of salicylic acid (SA)/jasmonic acid (JA) pathway genes and increased SA/JA levels, ultimately resulting in enhanced resistance. However, biotroph- and hemibiotroph-induced OsEIL2 targets OsERF083, resulting in the inhibition of SA/JA pathway genes and decreased SA/JA levels, ultimately leading to reduced resistance. Our findings unveil a previously uncharacterized defense mechanism wherein two distinct transcriptional regulatory modules differentially mediate immunity against pathogens with different lifestyles through the transcriptional reprogramming of phytohormone pathway genes.
Although natural supports benefit individuals with intellectual and developmental disabilities (IDD), little is known about natural support provided within specific life domains or how race/ethnicity or support from professionals impacts the extent of natural support one receives. In this study, 518 parents of adults with IDD responded to a national survey about natural supports, including who provides support, the number of supporters, and variables that predict natural supports. Family most often provided support, although professionals and family friends were frequent supporters in several domains. Natural support was most extensive in health, least extensive in employment and housing. Individuals with IDD who regularly participated in daytime activities and/or identified as Black had more extensive natural support. Implications are discussed.
In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
The present application relates to a fusion protein comprising: an antibody or antigen-binding fragment thereof that binds to C3 b; and a polypeptide that binds to C3b, wherein the polypeptide comprises: (i) An amino acid sequence according to SEQ ID NO. 11 or a variant thereof having at least 80% sequence identity to an amino acid sequence according to SEQ ID NO. 11; and (ii) the amino acid sequence according to SEQ ID NO. 12 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO. 12, wherein the antibody or antigen binding fragment thereof of the fusion protein does not compete with the polypeptide of the fusion protein for binding to C3 b. The application also provides polypeptides, nucleic acids, vectors and methods of making them, and methods of treatment and pharmaceutical compositions.
The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
The invention belongs to the field of biological medicines, and particularly relates to application of sPD1 protein and/or sPD1 gene as an immunologic adjuvant in preparation of recombinant HPV vaccine. In the application, the sPD1 protein contains an amino acid sequence shown as SEQ ID NO. 3, or an amino acid sequence with the same function obtained by deleting, inserting or replacing the amino acid sequence shown as SEQ ID NO. 3; the sPD1 gene contains a nucleotide sequence shown as SEQ ID NO. 1 or a nucleotide sequence with the same function obtained by deleting, inserting or replacing the nucleotide sequence shown as SEQ ID NO. 1. The sPD1 used as an immunologic adjuvant enhances the capacity of the HPV vaccine to stimulate the organism to produce antibodies, induce the organism to produce humoral immune response, stimulate lymphocytes to secrete IFN-gamma and stimulate the organism to produce cellular immune response.
Ballistic shields protect users from a variety of threats, including projectiles. Shield back-face deformation (BFD) is the result of the shield absorbing energy from a projectile and deforming towards the user. Back-face deformation can result in localized blunt loading to the upper extremity, where the shield is supported by the user and may cause injury through behind armour blunt trauma (BABT) mechanisms. Post-mortem human subject (PMHS) responses are critical to identify the injury risk in these high-rate scenarios and are used to quantify the injury tolerance. Two vulnerable locations along the upper extremity were investigated-the hand and forearm-using eight PMHS to identify the fracture threshold resulting from shield BABT loading conditions. Impacts delivered to the hand at 16.4 ± 0.8 m/s resulted in failure loads of 3818 ± 897 N, whilst the forearm impacts delivered at a similar velocity of 16.9 ± 1.9 m/s had lower failure loads at 3011 ± 656 N. The corresponding 10% risk of hand and forearm fractures (as measured on a modified WorldSID Anthropomorphic Test Device) were identified as 11.0 kN and 8.1 kN, respectively, which should be used when evaluating future designs of composite ballistic shields. This study is the first known investigation of the upper extremity to this high loading rate scenario and provides the foundation for future biomechanical research in the area of behind shield blunt trauma.
Disclosed is a compound preparation having an auxiliary effect of preventing and treating psychological depression in children and adolescents. The compound preparation comprises mineral and terpene components, a medicinal and edible component, a probiotic component, and a vitamin component. Clinical contrast tests show that the compound preparation can greatly reduce the HAM-D depression score of children and adolescents. Pharmacological tests on depression model mice show that the compound preparation obviously shortens the immobility time of tail suspension in mice and the immobility time during forced swim tests in mice, suggesting a very good anti-depression effect. The compound preparation is obviously superior to a single probiotic component or mineral component or medicinal and edible component. All the components supplement each other and have a synergistic effect, and the treatment effect is achieved at multiple target points. The compound preparation is safe, effective and free from toxicity and side effects.
Patients receive octreotide acetate IM as in arm I on day 1 and recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
FIELD: medicine, immunology, microbiology. SUBSTANCE: native culture of Y. pestis is grown by submerged method followed by deposit removal and its microfiltration. Microfiltration is carried out on pore with size 0.2 mcm in regiment of liquid tangential flow under working pressure 0.15-0.2 MPa and output 6-8 dm 3 .h -1  as measured for filtrate. Method provides acceleration for preparing concentrate of bacterial cells and enhancement the yield of concentrate per unit of medium volume simultaneously. EFFECT: improved preparing method, enhanced yield of cells. 3 tbl
Disclosed is an infusion preparation for nutrient supply use. It comprises a sugar, amino acids, electrolytes and a fat emulsion. It has an excellent shelf life without causing precipitation, denaturation and the like in spite of the simultaneous presence of these components. Also disclosed is a container filled with infusion liquids comprising a first and a second compartment separated from each other by a separation means, wherein an infusion liquid containing a fat emulsion and a sugar is included in the first compartment and another infusion liquid containing amino acids and electrolytes is included in the second compartment. Further disclosed are an infusion preparation comprising a fat emulsion and a sugar, and an infusion preparation comprising amino acids and electrolytes. An infusion preparation containing a sugar, amino acids, electrolytes and a fat emulsion can be obtained easily and aseptically upon use, by simply removing a separation means attached to the container and mixing the two infusion liquids.
Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with encephalitis is provided. The seizures associated with encephalitis may be atonic, focal seizures with impairment, focal seizures without impairment, and focal seizures with secondary generalisation. The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The CBD preparation may comprise CBD isolated from cannabis plant material or may be synthetic CBD. The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AED). The one or more concomitant AEDs may be selected from the group consisting of: levetiracetam, clobazam, lacosamide, and lamotrigine. The dose of CBD may be between 5 mg/kg/day to 50 mg/kg/day. A clinical trial is disclosed wherein patients diagnosed with encephalitis had a decrease in the amount of seizures after dosing with the CBD preparation and concomitant AEDs.
PURPOSE: To detect an isotype antibody which can not be detected through conventional AIDS diagnostic test by employing at least one kind of labeled antibody for detection specific to an isotype antibody. CONSTITUTION: A kind of HIV virus or a plurality of types of protein is separated from the serum of a patient under inspection and fixed on a carrier. The fixed protein is brought into contact with the serum of AIDS patient in order to capture the antibody immunologically. The fixed protein includes GAG, POL, a protein corresponding to ENV gene, peptide obtained therefrom, etc. After capturing the antigen, an isotype antibody is detected using labeled anti- antibodies including at least one kind specific to an isotype antibody, e.g. IgM, IgA and IgE. A vaccine composed of an HIV antigenic protein modified to induce an effector and an uninterruptive isotype antibody, and a novel serum therapy can also be provided.
In this two-armed, single center, randomised controlled 3-month trial, simple randomisation was followed and the randomisation sequence was computer generated by an independent statistician. Blinding of the allocated treatment was maintained to the data analyst and was exposed only after the assessment of outcomes. Adult women (≥ 18 years of age) with histological evidence of primary invasive breast cancer (BC) at stages I-IIIA, who underwent mastectomy followed by antiestrogen therapy, were enrolled in the study. Additional criterion was the ability to ambulate independently, that corresponded to scoring 0 or 1 of the Eastern Cooperative Oncology Performance Status.

At baseline before the start of the trial, each enrolled participant completed a personal interview with the appointed dieticians. In the Intervention group (or CDSS group), patients received a personalised daily dietary plan (specific meals, products, recipes, food portions in grams) based on the Meditteranean diet together with physical activity guidelines, all generated by a newly developed clinical decision support system (CDSS). During the trial, BC women were instructed to record food diaries in the CDSS every week (2 weekdays and 1 weekend day), which were also made available to the dieticians. Visiting the CDSS, patients had the opportunity to track their progress e.g. monitoring goals of body weight, physical activity, consumption of fruits, vegetables, legumes. Regular phone interviews were scheduled on 15-day basis to assist nutritional and lifestyle consultation, while unexpected phone calls were made to receive 24-hour dietary records.

The Control arm received general lifestyle guidelines based on the updated "American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention" via scheduled phone interviews every 15 days. Food diaries of each week (2 weekdays and 1 weekend day) were sent via emails and unexpected phone calls were made to receive 24-hour dietary records as well.

The appointed oncologist recorded medical history, including general information (age, sex, smoking) and disease specific data (i.e. cancer stage, type, age of diagnosis, symptoms and complications, and treatment). All assessments were carried out at the beginning and the end of the study (3 months). Body weight and body fat mass were measured with the method of Air Displacement Plethysmography. Dietary intake was evaluated using a semi-quantitative Food Frequency Questionnaire (FFQ), food diaries and 24h-recall records. The degree of Mediterranean diet adherence was estimated by the MedDiet score. The investigators also assessed performance status and physical activity, as well as quality of life and psychological distress by validated questionnaires. Our hypothesis was that the CDSS could be a useful means to provide nutritional care to BC patients ameliorating adherence to Mediterranean diet and the overall quality of life, during challenging periods like the COVID-19 pandemic.
This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
There are two aripiprazole formulations for intramuscular use with different dosages, dosing frequencies, and indications. ABILIFY MAINTENA is a long-acting aripiprazole formulation with 4-week dosing intervals indicated for the treatment of schizophrenia and maintenance monotherapy of bipolar I disorder in adults. In contrast, aripiprazole injection (9.75 mg per vial) is a short-acting formulation indicated for agitation in patients with schizophrenia or mania. Do not substitute these products. Refer to the prescribing information for aripiprazole injection for more information about aripiprazole injection.

ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe available in 300-mg or 400-mg strength syringes [see Dosage and Administration (2.5)], and 2) Single-use vials available in 300-mg or 400-mg strength vials [see Dosage and Administration (2.6)].

The 200-mg and 160-mg dosage adjustments are obtained only by using the 300-mg or 400-mg strength vials.
Heart failure (HF) is the terminal stage of various cardiovascular diseases. HF patient-caregiver dyads, who need to undertake the majority of HF care responsibility in the community, often experience a challenging adaptive process. There is a desperate need to develop and evaluate psychosocial dyadic interventions in HF patients and caregivers, as well as examine the working mechanism of such interventions. This sequential mixed-methods study consists of a single-blinded, two-arm randomized controlled trial (RCT) and a qualitative study. The dyads will be randomly allocated in a 1:1 ratio to the intervention group to receive a 12-week relationship-focused psychosocial dyadic programme, or to the control group to receive the usual care provided by the clinical team in the hospital. Besides, an empowerment-based approach will be employed in this programme to work together with patients and caregivers to set goals and develop an action plan to facilitate goal attainment. For the patients, Mutuality Scale, Connor-Davidson Resilience Scale, Self-Compassion Scale Short Form, Minnesota Living with Heart Failure Questionnaire, and Hospital Anxiety and Depression Scale will be administered at baseline, immediate and 3-month post-intervention. For the caregivers, the Mutuality Scale, Connor-Davidson Resilience Scale, Self-Compassion Scale Short Form, Family Caregiver Quality of Life Scale, and Hospital Anxiety and Depression Scale will be administered at baseline, immediate and 3-month post-intervention. A pilot study will be conducted to determine the feasibility, acceptability and preliminary effect of the intervention first. Afterwards, a full-scale mixed-methods study will be conducted to evaluate the effects of the intervention and the mechanism underlying the intervention.